TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34413160.
- Also identified by DOI 10.1158/1078-0432.CCR-21-2450.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prior treatment with anti-PD-1 and/or BRAF-targeted therapies was associated with limited activity of tumor infiltrating lymphocytes (TIL) in metastatic melanoma. Recent insights into mechanisms of action for TIL and anti-PD-1 provide the foundation for understanding differences in outcomes in different trials or populations, and a roadmap for developing improved products. See related article by Seitter et al., p. 5289.
Medical subject headings
- Melanoma
- Neoplasms, Second Primary